Fly News Breaks for February 3, 2020
Feb 3, 2020 | 07:10 EDT
H.C. Wainwright analyst Debjit Chattopadhyay initiated coverage of Harpoon Therapeutics with a Buy rating and $28 price target. Harpoon is advancing a proprietary platform of redirected T cell therapies, TriTACs, across solid tumors as well as multiple myeloma, Chattopadhyay tells investors in a research note. The analyst says demonstration of tumor trafficking and an adequate handle on cytokine release syndrome coupled with relevant biomarker data remain his base case expectation and underpin his Buy rating.
News For HARP From the Last 2 Days
There are no results for your query HARP